The price of Immuneering Corp (NASDAQ: IMRX) closed at $2.19 in the last session, down -6.81% from day before closing price of $2.35. In other words, the price has decreased by -$0.1600 from its previous closing price. On the day, 526680 shares were traded. IMRX stock price reached its highest trading level at $2.3600 during the session, while it also had its lowest trading level at $2.1700.
Ratios:
We take a closer look at IMRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 11.35 and its Current Ratio is at 11.35. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 15, 2024, Reiterated its Buy rating but revised its target price to $15 from $20 previously.
Jefferies Downgraded its Buy to Hold on March 15, 2024, whereas the target price for the stock was revised from $16 to $3.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 01 ’24 when Cormorant Asset Management, LP sold 400,000 shares for $2.90 per share. The transaction valued at 1,160,181 led to the insider holds 2,895,273 shares of the business.
Feinberg Peter bought 25,000 shares of IMRX for $63,713 on Mar 22 ’24. The Director now owns 111,766 shares after completing the transaction at $2.55 per share. On Mar 22 ’24, another insider, Brakewood Harold Eugene, who serves as the Chief Business Officer of the company, bought 3,900 shares for $2.57 each. As a result, the insider paid 10,015 and bolstered with 3,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMRX now has a Market Capitalization of 64.13M and an Enterprise Value of -17.07M. Its current Enterprise Value per Revenue stands at 191.91k whereas that against EBITDA is 0.29.
Stock Price History:
Over the past 52 weeks, IMRX has reached a high of $14.29, while it has fallen to a 52-week low of $1.90. The 50-Day Moving Average of the stock is 5.0579, while the 200-Day Moving Average is calculated to be 7.1705.
Shares Statistics:
According to the various share statistics, IMRX traded on average about 596.80K shares per day over the past 3-months and 694.31k shares per day over the past 10 days. A total of 29.27M shares are outstanding, with a floating share count of 20.62M. Insiders hold about 29.57% of the company’s shares, while institutions hold 55.17% stake in the company. Shares short for IMRX as of Mar 15, 2024 were 2.61M with a Short Ratio of 4.37, compared to 2.7M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.91% and a Short% of Float of 16.65%.
Earnings Estimates
The company has 9 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.5 for the current quarter, with a high estimate of -$0.22 and a low estimate of -$0.59, while EPS last year was -$0.51. The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.23 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$0.93 and -$2.38 for the fiscal current year, implying an average EPS of -$1.94. EPS for the following year is -$1.88, with 8 analysts recommending between -$0.83 and -$2.62.
